Ascendis Pharma A (ASND) Interest Expenses (2014 - 2026)

Ascendis Pharma A has reported Interest Expenses for 13 years, with the latest figure at $78.7 million in Q1 2026.

• Quarterly Interest Expenses rose 267.14% year-over-year to $78.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.5 million (up 14336.67% YoY) and the FY2025 annual result came in at $240.6 million, up 125.09% from the prior year.
• Interest Expenses rose to $78.7 million in Q1 2026 per ASND's latest filing, from $72.1 million in the prior quarter.
• Over five years, Interest Expenses peaked at $83.8 million in Q1 2024 and troughed at -$47.1 million in Q1 2025.
• A 5-year average of $27.4 million and a median of $21.1 million in 2024 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 519454.78% in 2025, down 156.2% in 2025.
• Over 5 years, Interest Expenses stood at -$314236.2 in 2022, then soared by 2984.71% to $9.1 million in 2023, then plunged by 100.15% to -$13891.7 in 2024, then soared by 519454.78% to $72.1 million in 2025, then gained by 9.14% to $78.7 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $78.7 million, $72.1 million, and $78.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.